Johnson & Johnson’s $5.5 billion settlement may seem like a resolution, but many victims and consumer advocates question its fairness. The deal uses a controversial bankruptcy tactic that critics say pressures claimants into accepting less than they deserve. The company’s two previous attempts using this same strategy were rejected by courts, raising concerns about coercion.
The settlement amount, while large in absolute terms, may not be enough considering the severity of ovarian cancer. Medical costs, lost wages, and pain and suffering can easily exceed individual payouts. The 25-year payment structure further dilutes the value, as victims in urgent need of cash may face prolonged waiting.
Moreover, the bankruptcy process shields J&J from full accountability. The company denies wrongdoing and avoids a public trial that could have revealed more evidence about product safety. This means victims never get a day in court, and the full story may remain hidden. For those seeking justice beyond money, the settlement feels hollow.
The requirement that 75% of claimants must approve the plan can also be troubling. It creates pressure on smaller claimants to accept terms that may benefit the company more than the victims. Some plaintiffs’ lawyers have already argued that the settlement undervalues claims and that the voting threshold could be met through aggressive tactics.
Additionally, the deal does not cover all related lawsuits, such as those filed by states or shareholders. It leaves some legal exposure on the table. And while J&J’s stock rose, that reflects investor relief rather than victim satisfaction.
In short, the settlement prioritizes finality over fairness. Victims deserve a thorough, transparent resolution that fairly compensates them for real harm, not a bankruptcy maneuver that limits their rights.